This is an X-PIL, which is a text only patient information leaflet, designed for people with sight problems.
Table of Contents
Novofem®
film-coated tablets
Estradiol and norethisterone acetate
1. What Novofem® is and what it is used for 2. Before you take Novofem® 3. How to use Novofem® 4. Possible side effects 5. How to store Novofem® 6. Further information
Novofem® is a sequential combined Hormone Replacement Therapy (HRT) which is taken every day without interruption. Novofem® is suitable for postmenopausal women with at least 6 months since their last natural period.
Novofem® contains 2 hormones, an oestrogen (estradiol) and a progestagen (norethisterone acetate). The estradiol in Novofem® is identical to the estradiol produced in the ovaries of women, and is classified as a natural oestrogen.
Norethisterone acetate is a synthetic progestagen, which acts in a similar manner as progesterone, another important female sex hormone.
The experience of treating women older than 65 years is limited.
The use of HRT carries risks which need to be considered when deciding whether to start taking it, or whether to carry on taking it.
Before you start (or restart) taking HRT, your doctor should ask about your own and your family’s medical history. Your doctor may decide to examine your breasts and/or your abdomen, and may do an internal examination — but only if these examinations are necessary for you, or if you have any special concerns.
Once you have started on Novofem®, you should see your doctor for regular check-ups (at least once a year). At these check-ups, your doctor may discuss the benefits and risks of continuing with Novofem®.
As well as regular check-ups with your doctor, be sure to:
If any of the following applies to you, talk to your doctor. Do not start taking Novofem®:
If you have (or have had) any of the following conditions, tell your doctor before you start the treatment. Your doctor may want to monitor you more closely.
These conditions may in rare cases come back or get worse during treatment with Novofem®:
If you are going to have surgery, make sure your doctor knows about it. You may need to stop taking HRT about 4 to 6 weeks before the operation to reduce the risk of a blood clot. Your doctor will tell you when you can start taking HRT again.
If you are experiencing any of the following conditions below, stop taking Novofem® and contact your doctor immediately:
Excessive thickening of the lining of the womb (endometrial hyperplasia) and cancer of the womb lining (endometrial cancer)
In women with an intact womb taking oestrogen-only HRT over a longer time, the risk of excessive thickening of the lining of the womb (endometrial hyperplasia) and cancer of the womb lining (endometrial cancer) is increased.
Taking a progestagen in addition to the oestrogen, such as Novofem®, helps to lower the extra risk.
Compare
In women who still have a womb and who are not taking HRT, on average 5 in 1,000 will be diagnosed with endometrial cancer between the ages of 50 and 65.
For women aged 50 to 65 who still have a womb and take oestrogen-only HRT, between 10 and 60 women in 1,000 will be diagnosed with endometrial cancer (i.e. between 5 and 55 extra cases), depending on the dose and for how long it is taken.
Breast cancer
Evidence suggests that taking combined oestrogen-progestagen and possibly also oestrogen-only HRT increases the risk of breast cancer. This depends on how long you take HRT. The additional risk is visible within a few years. However, it returns to normal within a few years (at most 5) after stopping treatment.
Women aged 50 to 79 who are not taking HRT, on average 9 to 14 in 1,000 will be diagnosed with breast cancer over a 5-year period.
For women aged 50 to 79 who are taking oestrogen-progestagen HRT over 5 years, there will be 13 to 20 cases in 1,000 users (i.e. an extra 4 to 6 cases).
Regularly check your breasts. See your doctor if you notice any changes such as:
Ovarian cancer
Ovarian cancer is rare. A slightly increased risk of ovarian cancer has been reported in women taking HRT for at least 5 to 10 years.
Women aged 50 to 69 who are not taking HRT, on average about 2 in 1,000 will be diagnosed with ovarian cancer over a 5-year period. For women who have been taking HRT for 5 years there will be between 2 and 3 cases per 1,000 users (i.e. up to 1 extra case).
Blood clots in a vein
(venous thromboembolism)
HRT increases the risk of blood clots in the veins 1.3- to 3-fold, especially during the first year of taking it.
Blood clots can be serious, and if one travels to the lungs, it can cause chest pain, breathlessness, fainting or even death.
You are generally more likely to get a blood clot in your veins if one or more of the following applies to you:
For signs of a blood clot, see “Stop taking Novofem®“ and see a doctor immediately.
Women in their 50s who are not taking HRT, on average over a 5-year period, 4 to 7 in 1,000 would be expected to get a blood clot in a vein.
For women in their 50s who have been taking oestrogen-progestagen HRT for over 5 years, there will be 9 to 12 in 1,000 users (i.e. an extra 5 cases).
Heart disease (heart attack)
There is no evidence that HRT will prevent a heart attack. Women over the age of 60 years taking oestrogen-progestagen HRT are slightly more likely to develop heart disease than those not taking any HRT.
Stroke
The risk of getting stroke is about 1.5 times higher in HRT users than in non-users. The number of extra cases of stroke due to use of HRT will increase with age.
Women in their 50s who are not taking HRT, on average 8 in 1,000 would be expected to have a stroke over a 5-year period.
For women in their 50s who are taking HRT, there will be 11 cases in 1,000 users over 5 years. (i.e. an extra 3 cases).
Other conditions
HRT will not prevent memory loss. The risk of probable memory loss may be somewhat higher in women who start using any kind of HRT after the age of 65.
Novofem® will cause a menstruation-like monthly bleeding (period), which usually occurs at the beginning of a new pack. If the periods get heavier than normal you should tell your doctor. However, some women may also experience breakthrough bleeding or spotting during the first few months of taking Novofem®. This kind of bleeding is different from the menstruation-like bleeding. If you have any breakthrough bleeding or spotting that continues for longer than the first few months, starts after some time on Novofem®, or continues even if you have stopped taking Novofem®, you should tell your doctor as soon as possible.
Some medicines may reduce the effect of Novofem®:
Other medicines may increase the effects of Novofem®:
Novofem® may have an impact on a concomitant treatment with cyclosporine.
Please tell your doctor or pharmacist, if you are taking or have recently taken any other medicines, even those not prescribed.
If you need a blood test, tell your doctor or the laboratory staff that you are taking Novofem®, because this medicine can affect the results of some tests.
Pregnancy: You should not take Novofem® if you are pregnant.
If you become pregnant while using Novofem® you should stop the treatment immediately and contact your doctor.
Breast-feeding: You should not use Novofem® if you are breast-feeding.
Ask your doctor or pharmacist for advice before taking any medicine.
Novofem® has no known effect on the ability to drive or use machines.
Novofem® contains lactose monohydrate.
If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.
Always take Novofem® exactly as your doctor has told you. You should check with your doctor or pharmacist if you are unsure.
If you are not switching from another hormone replacement therapy you can start treatment with Novofem® on any convenient day. If you are switching from another hormone replacement therapy ask your doctor when you should start treatment with Novofem®.
Take one tablet once a day, at about the same time each day.
Each pack contains 28 tablets
Days 1 – 16
Take one red tablet everyday for 16 days
Days 17 – 28
Take one white tablet everyday for 12 days
Take the tablets with a glass of water.
Once you have finished the pack, start a new pack continuing the treatment without interruption. A menstruation-like bleeding (period) usually occurs at the beginning of a new pack.
For further information on the use of the calendar pack see USER INSTRUCTIONS at the beginning of the package leaflet.
The lowest effective dose that gives you symptom relief should be used for the shortest duration when treating menopausal symptoms.
Talk to your doctor if you do not experience symptom relief after 3 months of treatment.
You should only continue treatment as long as the benefit outweighs the risk.
If you have taken more Novofem® than you should, talk to a doctor or pharmacist.
An overdose of Novofem® could make you feel sick or vomit.
If you forget to take your tablet at the usual time, take it within the next 12 hours. If more than 12 hours have gone by, start again as normal the next day. Do not take a double dose to make up for a forgotten tablet. Forgetting a dose may increase the likelihood of breakthrough bleeding and spotting.
If you would like to stop your treatment with Novofem® for any reason, please discuss your decision with your doctor, who will explain the effects of stopping treatment and discuss other possibilities with you.
If you have any further questions on the use of this product ask your doctor or pharmacist.
Like all medicines, Novofem® can have side effects, although not everybody gets them.
Hypersensitivity/allergy (uncommon side effect –affects 1 to 10 users in 1,000)
Though it is an uncommon event, hypersensitivity/allergy may occur. Signs of hypersensitivity/allergy may include one or more of the following symptoms: hives, itching, swelling, difficulty in breathing, low blood pressure (paleness and coldness of skin, rapid heart beat), feeling dizzy, sweating, which could be signs of anaphylactic reaction/shock. If one of the mentioned symptoms appears, stop taking Novofem® and seek immediate medical help.
The frequency of possible side effects listed below is defined using the following convention:
Very common (affects more than 1 user in 10)
Common (affects 1 to 10 users in 100)
Uncommon (affects 1 to 10 users in 1,000)
Rare (affects 1 to 10 users in 10,000)
Very rare (affects less than 1 user in 10,000)
Not known (frequency cannot be estimated from the available data)
Very common side effects
Common side effects
Uncommon side effects
Rare side effects
Very rare side effects
Other side effects of combined HRT
The following diseases are reported more often in women using HRT compared to women not using HRT:
If any of the side effects get serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.
Keep out of the reach and sight of children.
Do not use Novofem® after the expiry date which is stated on the label and outer carton after ‘EXP’. The expiry date refers to the last day of that month.
Do not store above 25°C. Do not refrigerate. Keep the container in the outer carton in order to protect from light.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.
The film-coated tablets are round with a diameter of 6 mm. The red tablets are engraved with NOVO 282. The white tablets are engraved with NOVO 283.
Each pack of 28 tablets contains 16 red tablets and 12 white tablets
Pack sizes available:
1 x 28 film-coated tablets
3 x 28 film-coated tablets
Not all pack sizes may be marketed
Supplied in Ireland by:
This medicinal product is authorised in the Member States of the EEA under the following names:
Member States of the EEA:
Novofem® – except for
France: Novofemme®
Spain: Duofemme®
This leaflet was last approved in: 09/2011
Novofem® is a trademark owned by Novo Nordisk FemCare AG, Switzerland
©2011
Novo Nordisk A/S
1. Set the day reminder Turn the inner disc to set the day of the week opposite the little plastic tab.2. Take the first day’s tablet Break the plastic tab and tip out the first tablet.3. Move the dial every day On the next day simply move the transparent dial clockwise 1 space as indicated by the arrow. Tip out the next tablet. Remember to take only 1 tablet once a day
You can only turn the transparent dial after the tablet in the opening has been removed.
8-2922-11-001-1
Link to this document from your website:http://www.medicines.ie/medicine/14557/XPIL/Novofem+Film-Coated+Tablets/